Taysha Gene Therapies, Inc.

Listed Company

TSHACIK 0001806310NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

$9.77M

Net Income

$-109.00M

Total Assets

$343.32M

Equity

$246.94M

Shares Out

287.36M

Op. Cash Flow

$-93.09M

TSHA$5.95+128.85% · past yearDBEQ Basic

Daily closing prices

Business

Taysha Gene Therapies is a clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic central nervous system diseases. Its lead program, TSHA-102, is in Phase 1/2 clinical trials for Rett syndrome, with pivotal Part B enrollment ongoing in the United States and Canada. The company also has early-stage pipeline programs in tauopathies, Fragile X syndrome, and other CNS disorders. It operates through licensed intellectual property from academic institutions and holds regulatory designations including orphan drug, rare pediatric disease, Fast Track, RMAT, and Breakthrough Therapy.

Summary from 10-K filed 2026-03-19

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	10	8	15	3	—
Research and development	86	66	57	91	132
General and administrative	34	29	30	37	41
Impairment of long-lived assets	0	5	1	36	0
Total operating expenses	120	100	88	165	173
Loss from operations	−110	−91	−72	−162	−173
Change in fair value of warrant liability	−1	16,000	−35	—	—
Change in fair value of term loan	−6	−5	−2	—	—
Interest income	9	7	4	—	—
Interest expense	−63,000	−102,000	−5	—	—
Other expense	−291,000	−110,000	−47,000	−18,000	—
Total other income, net	2	2	−39	−4	−1
Net loss	−109	−89	−112	−166	−175
Net loss per common share, basic	−0.34	−0.36	−0.96	−3.78	−4.64
Net loss per common share, diluted	−0.34	−0.36	−0.96	−3.78	−4.64
Weighted average common shares outstanding, basic	320	250	116	44	38
Weighted average common shares outstanding, diluted	320	250	116	44	38

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	320	139	144	88	149
Restricted cash	449,000	449,000	449,000	—	—
Prepaid expenses and other current assets	4	3	3	9	10
Total current assets	325	142	150	96	160
Restricted cash	2	2	2	3	—
Property, plant and equipment, net	7	7	11	15	51
Operating lease right-of-use assets	9	8	10	11	—
Other non-current assets	183,000	217,000	304,000	1	1
Total assets	343	160	173	126	214
Accounts payable	6	4	6	11	22
Accrued expenses and other current liabilities	20	13	12	18	30
Deferred revenue	—	10	18	34	—
Total current liabilities	27	26	37	63	52
Term loan, net	50	44	41	38	37
Operating lease liability, net of current portion	18	17	19	20	—
Other non-current liabilities	2	1	2	4	4
Total liabilities	96	89	98	125	119
Commitments and contingencies - Note 13	—	—	—	—	—
Preferred stock, $0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and December 31, 2024	—	—	—	—	—
Common stock, $0.00001 par value per share; 700,000,000 shares authorized and 285,051,648 issued and outstanding as of December 31, 2025 and 400,000,000 shares authorized and 204,943,306 issued and outstanding as of December 31, 2024	3,000	2,000	2,000	1,000	—
Additional paid-in capital	958	678	588	402	331
Accumulated other comprehensive loss	−192,000	−4	—	—	—
Accumulated deficit	−711	−602	−513	−401	−236
Total stockholders equity	247	72	75	949,000	95
Total liabilities and stockholders' equity	343	160	173	126	214

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−109	−89	−112	−166	−175
Depreciation expense	1	1	1	1	500,000
Stock-based compensation	13	13	8	18	18
Research and development license expense	3	—	4	1	—
Change in fair value of warrant liability	1	−16,000	35	—	—
Non-cash change in fair value of term loan	832,000	−597,000	1	—	—
Debt issuance costs expensed under the fair value option	147,000	—	867,000	—	—
Non-cash lease expense	1	1	1	1	—
Other	296,000	750,000	741,000	906,000	388,000
Prepaid expenses and other assets	−2	207,000	6	2	−3
Accounts payable	−153,000	−3	−2	−8	14
Accrued expenses and other liabilities	6	−1	−6	−9	18
Deferred revenue	−10	−8	−15	34	—
Net cash used in operating activities	−93	−81	−73	−88	−117
Purchase of property, plant and equipment	−738,000	−374,000	−4	−21	−15
Other	134,000	11,000	17,000	−61,000	—
Net cash used in investing activities	−604,000	−363,000	−7	−25	−22
Proceeds from issuance of common stock and pre-funded warrants from underwritten public offering, net of underwriting discounts and sales commissions and other offering costs	216	77	—	—	—
Proceeds from issuance of common stock pursuant to at-the-market offering, net of sales commissions and other offering costs	48	—	—	—	—
Prepayment of 2023 Trinity term loan	−41	—	—	—	—
Proceeds from 2025 Trinity term loan, net	50	—	—	—	—
Proceeds from issuance of common stock upon exercise of warrants	225,000	—	—	—	—
Debt issuance costs for term loan	—	−18,000	−399,000	—	—
Proceeds from common stock issuances under ESPP	159,000	89,000	68,000	253,000	—
Proceeds from stock option exercises	1	—	—	—	—
Other	−337,000	−167,000	−229,000	−1	−514,000
Net cash provided by financing activities	275	77	136	52	39
Net increase (decrease) in cash, cash equivalents and restricted cash	181	−5	56	−61	−100
Cash paid for interest	5	5	5	3	641,000
Proceeds allocated to Success Fee liability	217,000	—	—	—	—
Right-of-use assets obtained in exchange for lease liabilities	2	—	—	—	—
Purchase of research and development license not yet paid	3	—	—	—	4
Non-cash impact of exercise of liability classified warrants	2	—	74	—	—
Property, plant and equipment in accounts payable and accrued expenses	41,000	346,000	—	4	8
Offering costs not yet paid	—	46,000	18,000	387,000	141,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Taysha Gene Therapies, Inc.'s CIK number?

Taysha Gene Therapies, Inc.'s SEC CIK number is 0001806310 (1806310). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Taysha Gene Therapies, Inc.'s SEC filings?

All of Taysha Gene Therapies, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Taysha Gene Therapies, Inc. last report earnings?

Taysha Gene Therapies, Inc. (TSHA) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-207633). This is Taysha Gene Therapies, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Taysha Gene Therapies, Inc.'s most recent earnings 8-K?

Taysha Gene Therapies, Inc.'s latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001193125-26-207633. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Taysha Gene Therapies, Inc.'s latest earnings 8-K →
Look up any company's CIK number →